company background image
MEDP

Medpace HoldingsNasdaqGS:MEDP Stock Report

Market Cap

US$7.6b

7D

14.7%

1Y

94.8%

Updated

26 Oct, 2021

Data

Company Financials +
MEDP fundamental analysis
Snowflake Score
Valuation1/6
Future Growth3/6
Past Performance5/6
Financial Health6/6
Dividends0/6

MEDP Overview

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia.

Medpace Holdings Competitors

IQVIA Holdings

NYSE:IQV

US$48.9b

Avantor

NYSE:AVTR

US$22.9b

ICON

NasdaqGS:ICLR

US$22.7b

Charles River Laboratories International

NYSE:CRL

US$21.7b

Price History & Performance

Summary of all time highs, changes and price drops for Medpace Holdings
Historical stock prices
Current Share PriceUS$213.02
52 Week HighUS$105.48
52 Week LowUS$217.31
Beta1.3
1 Month Change7.47%
3 Month Change21.94%
1 Year Change94.75%
3 Year Change345.18%
5 Year Change632.28%
Change since IPO659.70%

Recent News & Updates

Oct 11
A Look At The Fair Value Of Medpace Holdings, Inc. (NASDAQ:MEDP)

A Look At The Fair Value Of Medpace Holdings, Inc. (NASDAQ:MEDP)

Does the October share price for Medpace Holdings, Inc. ( NASDAQ:MEDP ) reflect what it's really worth? Today, we will...

Aug 20
Is Now An Opportune Moment To Examine Medpace Holdings, Inc. (NASDAQ:MEDP)?

Is Now An Opportune Moment To Examine Medpace Holdings, Inc. (NASDAQ:MEDP)?

Medpace Holdings, Inc. ( NASDAQ:MEDP ), might not be a large cap stock, but it saw a double-digit share price rise of...

Shareholder Returns

MEDPUS Life SciencesUS Market
7D14.7%2.7%0.9%
1Y94.8%36.1%33.4%

Return vs Industry: MEDP exceeded the US Life Sciences industry which returned 36.9% over the past year.

Return vs Market: MEDP exceeded the US Market which returned 33.4% over the past year.

Price Volatility

Is MEDP's price volatile compared to industry and market?
MEDP volatility
MEDP Beta1.3
Industry Beta0.97
Market Beta1

Stable Share Price: MEDP is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: MEDP's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19924,100August Troendlehttps://www.medpace.com

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.

Medpace Holdings Fundamentals Summary

How do Medpace Holdings's earnings and revenue compare to its market cap?
MEDP fundamental statistics
Market CapUS$7.62b
Earnings (TTM)US$182.47m
Revenue (TTM)US$1.09b

41.7x

P/E Ratio

7.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MEDP income statement (TTM)
RevenueUS$1.09b
Cost of RevenueUS$413.59m
Gross ProfitUS$679.91m
ExpensesUS$497.44m
EarningsUS$182.47m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

Oct 26, 2021

Earnings per share (EPS)5.10
Gross Margin62.18%
Net Profit Margin16.69%
Debt/Equity Ratio0%

How did MEDP perform over the long term?

See historical performance and comparison

Valuation

Is Medpace Holdings undervalued compared to its fair value and its price relative to the market?

41.74x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: MEDP ($213.02) is trading above our estimate of fair value ($201)

Significantly Below Fair Value: MEDP is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: MEDP is good value based on its PE Ratio (41.7x) compared to the US Life Sciences industry average (48.1x).

PE vs Market: MEDP is poor value based on its PE Ratio (41.7x) compared to the US market (18.3x).


Price to Earnings Growth Ratio

PEG Ratio: MEDP is poor value based on its PEG Ratio (3.5x)


Price to Book Ratio

PB vs Industry: MEDP is overvalued based on its PB Ratio (8.5x) compared to the US Life Sciences industry average (6.5x).


Future Growth

How is Medpace Holdings forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

11.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MEDP's forecast earnings growth (11.8% per year) is above the savings rate (2%).

Earnings vs Market: MEDP's earnings (11.8% per year) are forecast to grow slower than the US market (14.7% per year).

High Growth Earnings: MEDP's earnings are forecast to grow, but not significantly.

Revenue vs Market: MEDP's revenue (13.8% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: MEDP's revenue (13.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MEDP's Return on Equity is forecast to be high in 3 years time (20.7%)


Past Performance

How has Medpace Holdings performed over the past 5 years?

41.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MEDP has high quality earnings.

Growing Profit Margin: MEDP's current net profit margins (16.7%) are higher than last year (13.8%).


Past Earnings Growth Analysis

Earnings Trend: MEDP's earnings have grown significantly by 41.9% per year over the past 5 years.

Accelerating Growth: MEDP's earnings growth over the past year (47.2%) exceeds its 5-year average (41.9% per year).

Earnings vs Industry: MEDP earnings growth over the past year (47.2%) underperformed the Life Sciences industry 55.2%.


Return on Equity

High ROE: MEDP's Return on Equity (20.3%) is considered high.


Financial Health

How is Medpace Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: MEDP's short term assets ($641.2M) exceed its short term liabilities ($517.2M).

Long Term Liabilities: MEDP's short term assets ($641.2M) exceed its long term liabilities ($161.9M).


Debt to Equity History and Analysis

Debt Level: MEDP is debt free.

Reducing Debt: MEDP has no debt compared to 5 years ago when its debt to equity ratio was 25.1%.

Debt Coverage: MEDP has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: MEDP has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Medpace Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MEDP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MEDP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MEDP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MEDP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MEDP's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

August Troendle (65 yo)

29.25yrs

Tenure

US$1,132,115

Compensation

Dr. August James Troendle, M.D. has been the Chairman, Chief Executive Officer at Medpace Holdings, Inc. since July 1992 and served as its President since July 1992 until August 01, 2021. Dr. Troendle foun...


CEO Compensation Analysis

Compensation vs Market: August's total compensation ($USD1.13M) is below average for companies of similar size in the US market ($USD6.29M).

Compensation vs Earnings: August's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: MEDP's management team is considered experienced (2.8 years average tenure).


Board Members

Experienced Board: MEDP's board of directors are considered experienced (3.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Medpace Holdings, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Medpace Holdings, Inc.
  • Ticker: MEDP
  • Exchange: NasdaqGS
  • Founded: 1992
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$7.616b
  • Shares outstanding: 35.75m
  • Website: https://www.medpace.com

Number of Employees


Location

  • Medpace Holdings, Inc.
  • 5375 Medpace Way
  • Cincinnati
  • Ohio
  • 45227
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/26 22:42
End of Day Share Price2021/10/26 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.